Total Revenue for drugs treating non-Hodgkins lymphoma expected to grow to $4.7 billion by 2008.
Total Revenue for drugs treating non-Hodgkins lymphoma expected to grow to $ 4.7 billion by 2008.
(PRWEB) December 25, 2003
Research and Markets announces the addition of this exciting new report entitled “Patterns and Trends in Lymphoma R&D” to its offerings.
In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 1998. The American Cancer Society estimates that approximately 1.2 million new cancer cases were diagnosed in the year 2000 in the US. Overall annual costs associated with cancer currently amount to $ 107 billion in the United States alone. The worldwide anti-cancer market was valued at more than $ 15 billion in 1998 and is projected to nearly double by 2003. Approximately 30% of all collaborative deals are signed in the field of cancer.
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. According to the American Cancer Society, 60 900 new cases of lymphoma were predicted in 2002 in the U.S; 53 900 of which were Non-Hodgkin and 7 000 Hodgkin Lymphomas. Another 7000 Chronic Lymphatic Leukemias were predicted. The number of deaths were predicted to 25 800, 1 400, 24 400, and 4 500 respectively. The emerging non-Hodgkins lymphoma therapeutics market generated $ 1.14 billion in revenue in 2000, according to Frost & Sullivan. Total revenue for drugs treating all stages of non-Hodgkins lymphoma should grow to $ 4.7 billion by 2008.
Patters and Trends in Lymphoma R&D is one of the most comprehensive and up to date information sources currently available in the lymphoma R&D arena. Information about new innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. This report will give you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mecanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current lymphoma -pipeline.
This report includes information on more than 110 companies active in lymphoma R&D, information on more than 220 industry related lymphoma projects, Data from 139 clinical trials, Information on more than 40 preclinical projects, 98 graphs illustrating the most important relations between types of therapy, effects and mecanisms, advanced analysis of general and specific trends in the pipeline.
For a complete index of this report click on http://www.researchandmarkets.com/reports/41839
About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.
For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com
###
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
What youre saying is completely true. I know that everybody must say the same thing, but I just think that you put it in a way that everyone can understand. I also love the images you put in here. They fit so well with what youre trying to say. Im sure youll reach so many people with what youve got to say.